Last reviewed · How we verify

Universidad Autonoma de Nuevo Leon — Portfolio Competitive Intelligence Brief

Universidad Autonoma de Nuevo Leon pipeline: 2 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 2 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Betamethason Sodium Phosphate Betamethason Sodium Phosphate marketed
Acetaminophen 500mg Acetaminophen 500mg marketed
Botulinum Toxins, Type A Botulinum Toxins, Type A phase 3 Neurotoxin; Acetylcholine release inhibitor SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology; Dermatology; Aesthetics
Doxophylline Doxophylline phase 3 Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Croma-Pharma GmbH · 1 shared drug class
  2. EvergreenHealth · 1 shared drug class
  3. Helse Nord-Trøndelag HF · 1 shared drug class
  4. NICHD Pelvic Floor Disorders Network · 1 shared drug class
  5. University of Calgary · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Universidad Autonoma de Nuevo Leon:

Cite this brief

Drug Landscape (2026). Universidad Autonoma de Nuevo Leon — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidad-autonoma-de-nuevo-leon. Accessed 2026-05-17.

Related